Azt-pmap
Based on 1 Customer Validation
Azt-pmap, a nucleoside analogue, is an aryl phosphate derivative of AZT. Azt-pmap shows anti-HIV activity. AZT is a nucleoside reverse transcriptase inhibitor (NRTI) for HIV infection. Azt-pmap is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.85%
- No. CAS: 142629-81-0
- Fòrmula: C20H25N6O8P
- Peso molecular:508.42
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
IC50 & Target
[1]|
HIV-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | CC50 |
172 μM
Compound: 2a
|
cytotoxic activity in CEM/0 cell line
cytotoxic activity in CEM/0 cell line
|
[PMID: 8478904] |
| CCRF-CEM | CC50 |
172 μM
Compound: 4 ([PhMeAla]AZT)
|
Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.
Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.
|
10.1016/0960-894X(96)00195-3 |
| CCRF-CEM | CC50 |
9.7 x 10-5M
Compound: 4
|
Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1
Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1
|
[PMID: 9871705] |
| CCRF-CEM | EC50 |
0.055 μM
Compound: 2a
|
Anti HIV-1 activity in human lymphocyte CEM/0 cell line
Anti HIV-1 activity in human lymphocyte CEM/0 cell line
|
[PMID: 8478904] |
| CCRF-CEM | EC50 |
0.055 μM
Compound: 4 ([PhMeAla]AZT)
|
Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
|
10.1016/0960-894X(96)00195-3 |
| CCRF-CEM | EC50 |
0.07 μM
Compound: 2a
|
Anti HIV-2 activity in human lymphocyte CEM/0 cell line
Anti HIV-2 activity in human lymphocyte CEM/0 cell line
|
[PMID: 8478904] |
| CCRF-CEM | EC50 |
0.07 μM
Compound: 4 ([PhMeAla]AZT)
|
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
|
10.1016/0960-894X(96)00195-3 |
| CCRF-CEM | EC50 |
12 μM
Compound: 2a
|
Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase
Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase
|
[PMID: 8478904] |
| CCRF-CEM | EC50 |
12 μM
Compound: 4 ([PhMeAla]AZT)
|
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
|
10.1016/0960-894X(96)00195-3 |
| CCRF-CEM | EC50 |
4.1 x 10-6M
Compound: 4
|
Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1
Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1
|
[PMID: 9871705] |
| CEM-SS | CC50 |
>100 μM
Compound: 1
|
Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line
Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line
|
[PMID: 14521418] |
| CEM-SS | EC50 |
0.05 μM
Compound: 1
|
Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line
Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line
|
[PMID: 14521418] |
| CEM-TK(+) | CC50 |
>100 μM
Compound: 1
|
Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line
Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line
|
[PMID: 14521418] |
| JM1 | ED50 |
0.8 μM
Compound: 2d
|
Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control
Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control
|
10.1016/S0960-894X(00)80395-9 |
| MT4 | CC50 |
>10 μM
Compound: 1
|
Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line
Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line
|
[PMID: 14521418] |
| MT4 | CC50 |
>50 μM
Compound: 2a
|
cytotoxic activity in MT-4 cell line
cytotoxic activity in MT-4 cell line
|
[PMID: 8478904] |
| MT4 | EC50 |
0.006 μM
Compound: 2a
|
Anti HIV-1 activity in human lymphocyte MT-4 cell line
Anti HIV-1 activity in human lymphocyte MT-4 cell line
|
[PMID: 8478904] |
| MT4 | EC50 |
0.007 μM
Compound: 2a
|
Anti HIV-2 activity in human lymphocyte MT-4 cell line
Anti HIV-2 activity in human lymphocyte MT-4 cell line
|
[PMID: 8478904] |
| MT4 | EC50 |
0.34 μM
Compound: 1
|
Effective concentration required to inhibit HIV-1 replication in MT-4 cell line
Effective concentration required to inhibit HIV-1 replication in MT-4 cell line
|
[PMID: 14521418] |
In Vitro
Azt-pmap shows anti-HIV-1 activities in infected C8166 and JM cells with EC50s of 0.08 and0.32 μM, respectively. Azt-pmap displays toxicities in infected C8166 and JM cells with TC50s of 500 μM, respectively. Azt-pmap inhibits virus replication[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 142629-81-0
-
Appearance Solid
-
Peso molecular 508.42
-
Fòrmula C20H25N6O8P
-
Color White to off-white
-
SMILES
O=C(NC1=O)N(C=C1C)[C@@H]2O[C@H](COP(OC3=CC=CC=C3)(N[C@@H](C)C(OC)=O)=O)[C@@H](N=[N+]=[N-])C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (196.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. McGuigan C, et al. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antiviral Res. 1992 Apr;17(4):311-21. [Content Brief]
[2]. Gray LR, et al. The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One. 2013 Apr 16;8(4):e62196. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9669 mL | 9.8344 mL | 19.6688 mL | 49.1719 mL |
| 5 mM | 0.3934 mL | 1.9669 mL | 3.9338 mL | 9.8344 mL | |
| 10 mM | 0.1967 mL | 0.9834 mL | 1.9669 mL | 4.9172 mL | |
| 15 mM | 0.1311 mL | 0.6556 mL | 1.3113 mL | 3.2781 mL | |
| 20 mM | 0.0983 mL | 0.4917 mL | 0.9834 mL | 2.4586 mL | |
| 25 mM | 0.0787 mL | 0.3934 mL | 0.7868 mL | 1.9669 mL | |
| 30 mM | 0.0656 mL | 0.3278 mL | 0.6556 mL | 1.6391 mL | |
| 40 mM | 0.0492 mL | 0.2459 mL | 0.4917 mL | 1.2293 mL | |
| 50 mM | 0.0393 mL | 0.1967 mL | 0.3934 mL | 0.9834 mL | |
| 60 mM | 0.0328 mL | 0.1639 mL | 0.3278 mL | 0.8195 mL | |
| 80 mM | 0.0246 mL | 0.1229 mL | 0.2459 mL | 0.6146 mL | |
| 100 mM | 0.0197 mL | 0.0983 mL | 0.1967 mL | 0.4917 mL |
Azt-pmap Related Classifications
HY-120832 Related Classifications
Powered by Bioz